We Offer Worldwide Shipping
Login Wishlist

4-Hydroxy-11(13)-eudesmen-12-oic acid

$960

  • Brand : BIOFRON

  • Catalogue Number : BN-O1534

  • Specification : 98%(HPLC)

  • CAS number : 4586-68-9

  • Formula : C15H24O3

  • Molecular Weight : 252.4

  • PUBCHEM ID : 6452036

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1534

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

252.4

Appearance

Powder

Botanical Source

This product is isolated and purified from the bark of Laggera pterodonta

Structure Type

Sesquiterpenoids

Category

Standards;Natural Pytochemical;API

SMILES

CC12CCCC(C1CC(CC2)C(=C)C(=O)O)(C)O

Synonyms

2-Naphthaleneacetic acid, decahydro-8-hydroxy-4a,8-dimethyl-α-methylene-, (2R,4aR,8R,8aR)-/2-[(2R,4aR,8R,8aR)-8-Hydroxy-4a,8-dimethyldecahydro-2-naphthalenyl]acrylic acid/2-[(2R,4aR,8R,8aR)-8-hydroxy-4a,8-dimethyldecahydronaphthalen-2-yl]prop-2-enoic acid

IUPAC Name

2-[(2R,4aR,8S,8aR)-8-hydroxy-4a,8-dimethyl-1,2,3,4,5,6,7,8a-octahydronaphthalen-2-yl]prop-2-enoic acid

Density

1.1±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

209.5±19.7 °C

Boiling Point

399.4±25.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C15H24O3/c1-10(13(16)17)11-5-8-14(2)6-4-7-15(3,18)12(14)9-11/h11-12,18H,1,4-9H2,2-3H3,(H,16,17)/t11?,12?,14-,15-/m1/s1

InChl Key

FXKCXGBBUBCRPU-BBNOBNGHSA-N

WGK Germany

RID/ADR

HS Code Reference

2918190000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:4586-68-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

2885839

Abstract

The murine epidermis is a heterogeneous epithelium composed of keratinocytes, melanocytes, Langerhans cells, and a recently described subpopulation (2-3%) of bone-marrow-derived leukocytes with a dendritic morphology and the cell surface phenotype Thy-1+, L3T4-, Lyt-2-. Previous studies have demonstrated that cell lines derived from freshly explanted Thy-1+ dendritic epidermal cells (DEC) have abundant mRNA for rearranged T-cell receptor (TCR) gamma-chain genes. Analysis of Thy-1+ DEC in situ, freshly isolated cell suspensions of Thy-1+ DEC, and long-term Thy-1+ DEC lines demonstrated that 100% of the Thy-1+ DEC reacted with a monoclonal antibody to the epsilon chain of the murine T3 complex and that 40-60% of resident Thy-1+ DEC were also reactive with an antiserum to the TCR gamma chain. Two Thy-1+ DEC lines expressed a disulfide-linked 70-kDa molecule that could be precipitated with an anti-gamma-chain antiserum and could be coprecipitated with an antiserum to the T3 delta chain; the molecule appeared as a single 34-kDa band under reducing conditions. The phenotype of Thy-1+ DEC (T3+, L3T4-, Lyt-2-, TCR gamma chain+) thus resembles that of the recently described subpopulation of murine and human lymphocytes that have been identified in the thymus, peripheral blood, and fetal blood.

Title

Thy-1+ dendritic epidermal cells express T3 antigen and the T-cell receptor gamma chain

Author

G Stingl, F Koning, H Yamada, W M Yokoyama, E Tschachler, J A Bluestone, G Steiner, L E Samelson, A M Lew, J E Coligan

Publish date

1987 Jul;

PMID

8890211

Abstract

Protein D, a surface-exposed 42-kDa membrane lipoprotein, is well conserved among both type b and nontypeable Haemophilus influenzae strains, and it is considered a vaccine against H. influenzae infections. Here, we report the large-scale purification of a nonacylated form of protein D (PDm) from the periplasmic space of Escherichia coli overexpressing PDm. Screening of human sera for levels of antibodies to PDm demonstrated that the immunoglobulin G (IgG) antibody level is above background levels in infants less than 6 months of age. Following a drop to background values in the age group 6 months to 1 year, IgG antibody levels start to increase, together with IgA antibody levels, after 1 year of age. The first appearance of serum IgM antibodies is in 6-month- to 1-year-old infants whose IgG antibody levels have dropped to the postnatal background level. Affinity-purified antibodies from humans and from PDm-immunized rats detected epitopes of protein D which are normally exposed on the bacterial surface. Affinity-isolated human anti-PDm antibodies eluted in acidic buffer were not bactericidal against H. influenzae. Loss of bactericidal activity may occur in this buffer, as was demonstrated in pooled human sera with high bactericidal activity after incubation in the same buffer. Hyperimmunization of rats with PDm induced high levels of serum IgG and IgA antibodies against PDm and significant bactericidal activity against homologous and heterologous H. influenzae strains.

Title

Biological activity of serum antibodies to a nonacylated form of lipoprotein D of Haemophilus influenzae.

Author

M Akkoyunlu, H Janson, M Ruan, and A Forsgren

Publish date

1996 Nov;

PMID

27020112

Abstract

Purpose
Survivors of pediatric Hodgkin Lymphoma (HL) are recognized to be at increased risk for delayed adverse health outcomes related to radiation therapy (RT). However, the necessary latency required to observe these late effects means that the estimated risks apply to out-dated treatments. We sought to compare the normal tissue dose received by children treated for HL and enrolled in the Childhood Cancer Survivor Study (CCSS) (diagnosed 1970-1986) with patients treated on recent Children’s Oncology Group (COG) trials (enrolled 2002-2012).

Methods
RT treatment planning data were obtained for 50 HL survivors randomly sampled from the CCSS cohort and applied to CT planning datasets to reconstruct normal tissue dosimetry. For comparison, normal tissue dosimetry was obtained for all 191 patients with full CT-based volumetric RT planning on COG protocols AHOD0031 and AHOD0831.

Results
For early stage patients, mean female breast dose in the COG patients was on average 83.5% lower than CCSS patients, with an absolute reduction of 15.5Gy; for advanced stage patients mean breast dose decreased on average by 70% (11.6Gy average absolute dose reduction). The mean heart dose decreased on average by 22.9Gy (68.6%), and 17.6Gy (56.8%) for early and advanced stage patients, respectively. All dose comparisons for breast, heart, lung, and thyroid were significantly lower for patients on COG trials than CCSS participants. Reduction in prescribed dose was a major contributor to this dose reduction.

Conclusions
These are the first data quantifying the significant reduction in normal tissue dose based on actual rather than hypothetical treatment plans for children with HL. The findings provide some useful information when counselling families regarding the risks of contemporary RT.

Title

A Comparative Evaluation of Normal Tissue Doses for Patients Receiving Radiation Therapy for Hodgkin Lymphoma on the Childhood Cancer Survivor Study and Recent Children's Oncology Group Trials

Author

Rachel Zhou, MRT(T), HBSc,1 Angela Ng, MEd, MRT(T),1 Louis S. Constine, MD,2 Marilyn Stovall, PhD,3 Gregory T. Armstrong, MD, MSCE,4 Joseph P. Neglia, MD, MPH,5 Debra L. Friedman, MD,6 Kara Kelly, MD,7 Thomas J. FitzGerald, MD,8,9 and David C. Hodgson, MD, MPH10

Publish date

2017 Jun 1.


Description :

Empty ...